CTMX250117P1000
- 0.05
- 0.000.00%
CytomX Newsroom
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.25
Wedbush Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $5
CytomX Therapeutics (CTMX) Receives a Buy From Wedbush
Express News | CytomX Therapeutics Inc : Wedbush Cuts Target Price to $5 From $8
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeuticsto Neutral
CytomX Therapeutics Analyst Ratings
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
CytomX Therapeutics to Cut 40% of Workforce
CytomX Therapeutics Focuses on Lead Program CX-2051 and Streamlines Operations for 2025
CytomX Therapeutics: Ended 3Q With $117.6M of Cash, Cash Equivalents and Investments >CTMX
Express News | CytomX Therapeutics Inc -CytomX Will Reduce Organizational Headcount by Approximately 40 Percent
Express News | CytomX Therapeutics Inc -Revised Focus and Associated Cost and Headcount Reductions Expected to Extend Cash Runway Into Q2 of 2026
Express News | CytomX Therapeutics Inc - Initial Phase 1a Data for Cx-2051 Expected in H1 2025
Express News | CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
CytomX Heading Into 'Major Catalyst Year,' Says JonesResearch
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
Here's Why Agios Stock Plummeted More Than 20% on Monday